Back to Journals » Pharmacogenomics and Personalized Medicine » Volume 9

The effect of ABCB1 polymorphisms on the outcome of breast cancer treatment

Authors Tulsyan S, Mittal R, Mittal B

Received 7 November 2015

Accepted for publication 13 January 2016

Published 27 April 2016 Volume 2016:9 Pages 47—58

DOI https://doi.org/10.2147/PGPM.S86672

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Henrik Rasmussen

Peer reviewer comments 4

Editor who approved publication: Dr Martin H. Bluth


Sonam Tulsyan,1 Rama Devi Mittal,2 Balraj Mittal1

1Department of Genetics, 2Department of Urology and Renal Transplant, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

Abstract: The ABCB1 gene encodes a permeability glycoprotein, which is one of the most extensively studied human adenosine-triphosphate (ATP)-dependent efflux transporters. Permeability glycoprotein is expressed in the apical membranes of tissues such as intestine, liver, blood–brain barrier, kidney, placenta, and testis and contributes to intracellular drug disposition. It is also highly expressed in tumor cells conferring drug resistance, which is one of the major problems in the efficacy of cancer chemotherapy treatment. ABCB1 is highly polymorphic, and three well-known single-nucleotide polymorphisms such as 1236C>T, 2677G>T/A, and 3435C>T have been found to be associated with altered messenger RNA levels, protein folding, and drug pharmacokinetics. Many association studies and meta-analyses have demonstrated the clinical impact of ABCB1 polymorphisms in breast cancer treatment outcomes with respect to therapeutic response, chemotoxicity, and overall survival. Therefore, the aim of this review was to evaluate the effects of ABCB1 polymorphisms on the outcome of breast cancer treatment which, in future, would be important for tailoring individualized anticancer therapy.

Keywords: ABCB1, P-glycoprotein, polymorphisms, breast cancer treatment, chemotherapy, response, drug resistance

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]